{"id":19547,"date":"2022-06-03T08:08:52","date_gmt":"2022-06-03T15:08:52","guid":{"rendered":"https:\/\/marketdepth.com\/?p=19547"},"modified":"2022-06-03T08:08:54","modified_gmt":"2022-06-03T15:08:54","slug":"turning-point-therapeutics-to-be-acquired-by-bristol-myers-squibb","status":"publish","type":"post","link":"https:\/\/marketdepth.com\/turning-point-therapeutics-to-be-acquired-by-bristol-myers-squibb\/","title":{"rendered":"Turning Point Therapeutics to be Acquired by Bristol Myers Squibb"},"content":{"rendered":"\n

Bristol Myers Squibb (NYSE: BMY) and Turning Point therapeutics, Inc. (NASDAQ: TPTX) has announced<\/a> a definitive merger agreement under which Bristol Myers Squibb will acquire Turning Point therapeutics for USD 76 per share.\u00a0 This transaction was approved by both company board of directors and is expected to close\u00a0 during the third quarter of 2022. \u201cThe acquisition of Turning Point Therapeutics further broadens our leading oncology franchise by adding a best-in-class, late-stage precision oncology asset,\u201d said Giovanni Caforio, M.D., Board Chair and Chief Executive Officer, Bristol Myers Squibb. \u201cWith this transaction, we are continuing our strong track record of strategic business development to further enhance our growth profile.\u201d<\/p>\n\n\n\n

\u201cToday\u2019s news builds upon our long legacy of pioneering next-generation medicines for patients with cancer. With repotrectinib, we have the opportunity to change the standard of care and address a significant unmet medical need for ROS1-positive non-small cell lung cancer patients.\u201d<\/p>Samit Hirawat, M.D., Chief Medical Officer, Global Drug Development, Bristol Myers Squibb<\/cite><\/blockquote>\n\n\n\n

\u201cThrough this transaction, we will be able to harness the full potential of our precision oncology platform to advance the standard of care for cancer patients. Since our founding, we have leveraged our deep scientific expertise to develop a pipeline of promising precision oncology assets,\u201d said Athena Countouriotis, M.D., President and Chief Executive Officer, Turning Point Therapeutics. \u201cWith Bristol Myers Squibb\u2019s leadership in oncology, strong commercial capabilities and manufacturing footprint, we will be able to further accelerate the pace at which we can bring our novel medicines to benefit people diagnosed with cancer around the world.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"Bristol Myers Squibb (NYSE: BMY) and Turning Point therapeutics, Inc. (NASDAQ: TPTX) has announced a definitive merger agreement under which Bristol Myers Squibb will acquire Turning Point therapeutics for USD 76 per share.\u00a0 This transaction was approved by both company board of directors and is expected to close\u00a0 during the third quarter of 2022. \u201cThe… View Article<\/a>","protected":false},"author":3,"featured_media":17769,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":0,"footnotes":""},"categories":[9,17,8,11,16],"tags":[],"acf":[],"yoast_head":"\nTurning Point Therapeutics to be Acquired by Bristol Myers Squibb - MarketDepth<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/marketdepth.com\/turning-point-therapeutics-to-be-acquired-by-bristol-myers-squibb\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Turning Point Therapeutics to be Acquired by Bristol Myers Squibb - MarketDepth\" \/>\n<meta property=\"og:description\" content=\"Bristol Myers Squibb (NYSE: BMY) and Turning Point therapeutics, Inc. (NASDAQ: TPTX) has announced a definitive merger agreement under which Bristol Myers Squibb will acquire Turning Point therapeutics for USD 76 per share.\u00a0 This transaction was approved by both company board of directors and is expected to close\u00a0 during the third quarter of 2022. \u201cThe... View Article\" \/>\n<meta property=\"og:url\" content=\"https:\/\/marketdepth.com\/turning-point-therapeutics-to-be-acquired-by-bristol-myers-squibb\/\" \/>\n<meta property=\"og:site_name\" content=\"MarketDepth\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/marketdepthnews\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-03T15:08:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-03T15:08:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/10\/CancerResearch.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1347\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"MarketDepth\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MarketDepthNews\" \/>\n<meta name=\"twitter:site\" content=\"@MarketDepthNews\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"MarketDepth\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/marketdepth.com\/turning-point-therapeutics-to-be-acquired-by-bristol-myers-squibb\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/marketdepth.com\/turning-point-therapeutics-to-be-acquired-by-bristol-myers-squibb\/\"},\"author\":{\"name\":\"MarketDepth\",\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69\"},\"headline\":\"Turning Point Therapeutics to be Acquired by Bristol Myers Squibb\",\"datePublished\":\"2022-06-03T15:08:52+00:00\",\"dateModified\":\"2022-06-03T15:08:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/marketdepth.com\/turning-point-therapeutics-to-be-acquired-by-bristol-myers-squibb\/\"},\"wordCount\":270,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/marketdepth.com\/#organization\"},\"articleSection\":[\"Biotechnology\",\"Headlines\",\"Healthcare\",\"Investing\",\"What's Hot\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/marketdepth.com\/turning-point-therapeutics-to-be-acquired-by-bristol-myers-squibb\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/marketdepth.com\/turning-point-therapeutics-to-be-acquired-by-bristol-myers-squibb\/\",\"url\":\"https:\/\/marketdepth.com\/turning-point-therapeutics-to-be-acquired-by-bristol-myers-squibb\/\",\"name\":\"Turning Point Therapeutics to be Acquired by Bristol Myers Squibb - MarketDepth\",\"isPartOf\":{\"@id\":\"https:\/\/marketdepth.com\/#website\"},\"datePublished\":\"2022-06-03T15:08:52+00:00\",\"dateModified\":\"2022-06-03T15:08:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/marketdepth.com\/turning-point-therapeutics-to-be-acquired-by-bristol-myers-squibb\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/marketdepth.com\/turning-point-therapeutics-to-be-acquired-by-bristol-myers-squibb\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/marketdepth.com\/turning-point-therapeutics-to-be-acquired-by-bristol-myers-squibb\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/marketdepth.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Turning Point Therapeutics to be Acquired by Bristol Myers Squibb\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/marketdepth.com\/#website\",\"url\":\"https:\/\/marketdepth.com\/\",\"name\":\"MarketDepth\",\"description\":\"Stock Market News & Headlines\",\"publisher\":{\"@id\":\"https:\/\/marketdepth.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/marketdepth.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/marketdepth.com\/#organization\",\"name\":\"MarketDepth\",\"url\":\"https:\/\/marketdepth.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg\",\"contentUrl\":\"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg\",\"width\":1500,\"height\":1000,\"caption\":\"MarketDepth\"},\"image\":{\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/marketdepthnews\",\"https:\/\/twitter.com\/MarketDepthNews\",\"https:\/\/www.instagram.com\/marketdepth\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69\",\"name\":\"MarketDepth\",\"url\":\"https:\/\/marketdepth.com\/author\/3\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Turning Point Therapeutics to be Acquired by Bristol Myers Squibb - MarketDepth","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/marketdepth.com\/turning-point-therapeutics-to-be-acquired-by-bristol-myers-squibb\/","og_locale":"en_US","og_type":"article","og_title":"Turning Point Therapeutics to be Acquired by Bristol Myers Squibb - MarketDepth","og_description":"Bristol Myers Squibb (NYSE: BMY) and Turning Point therapeutics, Inc. (NASDAQ: TPTX) has announced a definitive merger agreement under which Bristol Myers Squibb will acquire Turning Point therapeutics for USD 76 per share.\u00a0 This transaction was approved by both company board of directors and is expected to close\u00a0 during the third quarter of 2022. \u201cThe... View Article","og_url":"https:\/\/marketdepth.com\/turning-point-therapeutics-to-be-acquired-by-bristol-myers-squibb\/","og_site_name":"MarketDepth","article_publisher":"https:\/\/www.facebook.com\/marketdepthnews","article_published_time":"2022-06-03T15:08:52+00:00","article_modified_time":"2022-06-03T15:08:54+00:00","og_image":[{"width":1920,"height":1347,"url":"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/10\/CancerResearch.jpg","type":"image\/jpeg"}],"author":"MarketDepth","twitter_card":"summary_large_image","twitter_creator":"@MarketDepthNews","twitter_site":"@MarketDepthNews","twitter_misc":{"Written by":"MarketDepth","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/marketdepth.com\/turning-point-therapeutics-to-be-acquired-by-bristol-myers-squibb\/#article","isPartOf":{"@id":"https:\/\/marketdepth.com\/turning-point-therapeutics-to-be-acquired-by-bristol-myers-squibb\/"},"author":{"name":"MarketDepth","@id":"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69"},"headline":"Turning Point Therapeutics to be Acquired by Bristol Myers Squibb","datePublished":"2022-06-03T15:08:52+00:00","dateModified":"2022-06-03T15:08:54+00:00","mainEntityOfPage":{"@id":"https:\/\/marketdepth.com\/turning-point-therapeutics-to-be-acquired-by-bristol-myers-squibb\/"},"wordCount":270,"commentCount":0,"publisher":{"@id":"https:\/\/marketdepth.com\/#organization"},"articleSection":["Biotechnology","Headlines","Healthcare","Investing","What's Hot"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/marketdepth.com\/turning-point-therapeutics-to-be-acquired-by-bristol-myers-squibb\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/marketdepth.com\/turning-point-therapeutics-to-be-acquired-by-bristol-myers-squibb\/","url":"https:\/\/marketdepth.com\/turning-point-therapeutics-to-be-acquired-by-bristol-myers-squibb\/","name":"Turning Point Therapeutics to be Acquired by Bristol Myers Squibb - MarketDepth","isPartOf":{"@id":"https:\/\/marketdepth.com\/#website"},"datePublished":"2022-06-03T15:08:52+00:00","dateModified":"2022-06-03T15:08:54+00:00","breadcrumb":{"@id":"https:\/\/marketdepth.com\/turning-point-therapeutics-to-be-acquired-by-bristol-myers-squibb\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/marketdepth.com\/turning-point-therapeutics-to-be-acquired-by-bristol-myers-squibb\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/marketdepth.com\/turning-point-therapeutics-to-be-acquired-by-bristol-myers-squibb\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/marketdepth.com\/"},{"@type":"ListItem","position":2,"name":"Turning Point Therapeutics to be Acquired by Bristol Myers Squibb"}]},{"@type":"WebSite","@id":"https:\/\/marketdepth.com\/#website","url":"https:\/\/marketdepth.com\/","name":"MarketDepth","description":"Stock Market News & Headlines","publisher":{"@id":"https:\/\/marketdepth.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/marketdepth.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/marketdepth.com\/#organization","name":"MarketDepth","url":"https:\/\/marketdepth.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/","url":"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg","contentUrl":"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg","width":1500,"height":1000,"caption":"MarketDepth"},"image":{"@id":"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/marketdepthnews","https:\/\/twitter.com\/MarketDepthNews","https:\/\/www.instagram.com\/marketdepth\/"]},{"@type":"Person","@id":"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69","name":"MarketDepth","url":"https:\/\/marketdepth.com\/author\/3\/"}]}},"_links":{"self":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts\/19547"}],"collection":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/comments?post=19547"}],"version-history":[{"count":1,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts\/19547\/revisions"}],"predecessor-version":[{"id":19548,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts\/19547\/revisions\/19548"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/media\/17769"}],"wp:attachment":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/media?parent=19547"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/categories?post=19547"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/tags?post=19547"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}